The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology(668 views) Giuffrida ML, Caraci F, De Bona P, Pappalardo G, Nicoletti F, Rizzarelli E, Copani A
Department of Pharmaceutical Sciences, University of Catania, Viale Andrea Doria 6, Catania 95125, Italy.
I.N.B.B. Fellowship, Pozzilli, Italy
Department of Chemical Sciences, University of Catania, Pozzilli, Italy
Institute of Biostructure and Bioimaging, National Research Council, Viale Andrea Doria 6, 95125, Catania, Italy
Department of Human Physiology and Pharmacology, University of Rome, “La Sapienza”, Piazzale Aldo Moro 5, 00185, Rome, Italy
Institute Neurologico, Mediterraneo, Neuromed, Località Camerelle, 86077, Pozzilli, Italy
References: Abramov, E., Dolcv, I., Fogel, I.I., Ciccotosto, G.D., Ruff, E., Slutsky, I., Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses (2009) Nat Neurosci, 12, pp. 1567-157
Adekar, S.P., Klyubin, I., Macy, S., Rowan, M.J., Solomon, A., O'Nuallain, B., Inherent anti-amyloidogenic activity of human Ig {gamma} heavy chains (2010) J Biol Chem, 285 (2), pp. 1066-1074
Amijee, H., Madine, J., Middleton, D.A., Doig, A.J., Inhibitors of protein aggregation and toxicity (2009) Biochem Soc Trans, 37, pp. 692-696
Bica, L., Crouch, P.J., Cappai, R., White, A.R., Metallocomplex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer's disease. Mo) (2009) Biosyst, 5, pp. 134-142
Blackley, H.K., Sanders, G.H., Davies, M.C., Roberts, C.J., Tendier, S.J., Wilkinson, M.J., In-situ atomic force microscopy study of beta-amyloid fibrillization (2000) J Mol Biol., 298, pp. 833-840
Brody, D.L., Magnoni, S., Schwetye, K.E., Spinner, M.L., Esparza, T.J., Stocchetti, N., Zipfel, G.J., Holtzman, D.M., Amyloid-beta dynamics correlate with neurological status in the injured human brain (2008) Science, 321, pp. 1221-1224
Check, E., Nerve inflammation halts trial for Alzheimer's drug (2002) Nature, 415, p. 462
Cirrito, J.R., May, P.C., O'Dell, M.A., Taylor, J.W., Pnrsadanian, M., Cramer, J.W., Audia, J.E., Holtzman, D.M., In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life (2003) J. Neuro. sci., 23, pp. 8844-8853
Crouch, P.J., Hung, L.W., Adlard, P.A., Cortes, M., Lai, V., Filiz, G., Perez, K.A., Barnham, K.J., Increasing Cu bio-availability inhibits Abeta oligomers and tau phosphorylation (2009) Proc Natl Acad Sci USA, 106, pp. 381-386
Dawson, G.R., Seabrook, G.R., Zheng, H., Smith, D.W., Graham, S., O'Dowd, G., Bowery, B.J., Sirinathsinghji, D.J., Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the betaamyloid precursor protein (1999) Neuroscience, 90, p. 113
De Bona, P., Giuffrida, M.L., Caraci, F., Copani, A., Pignataro, B., Attanasio, F., Cataldo, S., Rizzarelli, E., Design and synthesis of new trehaloseconjugated pentapeptides as inhibitors of Abeta(1-42) fibrillogenesis and toxicity (2009) J Pept Sci, 15, pp. 220-228
Dela Monte, S.M., Wands, J.R., Review of insulin and insulin like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease (2005) J Alzheimers Dis, 7, pp. 45-61
Dineley, K.T., Bell, K.A., Bui, D., Sweatt, J.D., beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes (2002) J Biol Chem, 277, pp. 25056-25061
Doble, A., The role of excitotoxicity in neurodegenerative disease: implications for therapy (1999) Pharmacol Ther, 81, pp. 163-121
Doig, A.J., Peptide inhibitors of beta-amyloid aggregation (2007) Curr Opin Drug Discov Devel, 10, pp. 533-539
Eckman, E.A., Eckman, C.B., Abeta-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention (2005) Biochem Soc Trans, 33, pp. 1101-1105
Fleisher, A.S., Raman, R., Siemers, E.R., Becerra, L., Clark, C.M., Dean, R.A., Farlow, M.R., Thai, L.J., Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease (2008) Arch Neurol, 65, pp. 1031-1038
Garcia-Osta, A., Alberini, C.M., Amyloid beta mediates memory formation (2009) Learn Mem., 16, pp. 267-272
Gong, Y., Chang, L., Viola, K.L., Lacor, P.N., Lambert, M.P., Finch, C.E., Krafft, G.A., Klein, W.L., Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss (2003) Proc Natl Acad Sci USA, 100, pp. 10417-10422
Green, R.C., Schneider, L.S., Amato, D.A., Beelen, A.P., Wilcock, G., Swabb, E.A., Zavitz, K.H., Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial (2009) JAMA, 302, pp. 2557-2564
Gu, Z., Liu, W., Van, Z., {beta}-Amyloid impairs AMP A receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution (2009) J Biol Chem, 284, pp. 10639-10649
Hansson, O., Zetterberg, H., Buchhave, P., Andreasson, U., Londos, E., Minthon, L., Blennow, K., Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment (2007) Dement Geriatr Cogn Disord, 23, pp. 316-320
Hardy, J., The shorter amyloid cascade hypothesis (1999) Neurobiol Aging., 20, pp. 85-87. , discussion
Harrison, S.M., Harper, A.J., Hawkins, J., Duddy, G., Grau, E., Pugh, P.L., Winter, P.H., Dingwall, C., BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes (2003) Mol Cell Neurosci, 24, pp. 646-655
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R.W., Nicoll, J.A., Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase 1 trial (2008) Lancet, 372, pp. 216-223
Kamenetz, F., Tomita, T., Hsieh, H., Seabrook, G., Borchelt, D., Iwatsubo, T., Sisodia, S., Malinow, R., APP processing and synaptic function (2003) Neuron, 37, pp. 925-937
Kim, H.J., Chae, S.C., Lee, D.K., Chromy, B., Lee, S.C., Park, Y.C., Klein, W.L., Hong, S.T., Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein (2003) FASEB J, 17, pp. 118-120
Klyubin, I., Walsh, D.M., Lemere, C.A., Cullen, W.K., Shankar, G.M., Betts, V., Spooner, E.T., Rowan, M.J., Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo (2005) Nat Med, 11, pp. 556-561
Kokjohn, T.A., Roher, A.E., Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial (2009) CNS Neurol Disord Drug Targets, 8, pp. 88-97
Lambert, M.P., Velasco, P.T., Viola, K.L., Klein, W.L., Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins (2009) CNS Neurol Disord Drug Targets, 8, pp. 65-81
Lambert, M.P., Barlow, A.K., Chromy, B.A., Edwards, C., Freed, R., Liosatos, M., Morgan, T.E., Klein, W.L., Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins (1998) Proc Natl Acad Sci USA, 95, pp. 6448-6453
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C.L., Ritchie, C.W., Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase Ha, double-blind, randomised, placebo-controlled trial (2008) Lancet Neurol, 7, pp. 779-786
Lee, D.H., Wang, H.Y., Differential physiologic responses of alpha7 nicotinic acetylcholine receptors to beta-amyloid 1-40 and beta-amyloid 1-42 (2003) J Neurobiol, 55, pp. 25-30
Lemere, C.A., Developing novel immunogens for a safe and effective Alzheimer's disease vaccine (2009) Prog Brain Res, 175, pp. 83-93
Leow, A.D., Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensorbased morphometry correlating degenerative rates, biomarkers and cognition (2009) Neuroimage, 45, pp. 645-655
Lesne, S., Koh, M.T., Kotilinek, L., Kayed, R., Glabe, C.G., Yang, A., Gallagher, M., Ashe, K.H., A specific amyloid-beta protein assembly in the brain impairs
memory (2006) Nature, 440, pp. 352-357
Li, L., Holscher, C., Common pathological processes in Alzheimer disease and type 2 diabetes: a review (2007) Brain Res Rev, 56, pp. 384-402
Lue, L.F., Kuo, Y.M., Roher, A.E., Brachova, L., Shen, Y., Sue, L., Beach, T., Rogers, J., Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease (1999) Am J Pathol, 155, pp. 853-862
Mackic, J.B., Stins, M., McComb, J.G., Calero, M., Ghiso, J., Kim, K.S., Yan, S.D., Zlokovic, B.V., Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer (1998) J Clin Invest, 102, pp. 734-743
McLean, C.A., Chemy, R.A., Fräser, F.W., Fuller, S.J., Smith, M.J., Beyreuther, K., Bush, A.L., Masters, C.L., Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease (1999) Ann Neurol, 46, pp. 860-866
Mollenhauer, B., Bibl, M., Trenkwalder, C., Stiens, G., Cepek, L., Steinacker, P., Ciesielczyk, B., Otto, M., Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease (2005) J Neural Transm, 112, pp. 933-948
Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling (2008) Neurobiol Aging, 31, pp. 224-243
Muller, U., Cristina, N., Li, Z.W., Wolfer, D.P., Lipp, H.P., Rulicke, T., Brandner, S., Weissmann, C., Behavioral and anatomical deficits in mice homozygous for a modified beta-amyloid pre-cursor protein gene (1994) Cell, 79, pp. 755-765
Nicoll, J.A., Wilkinson, D., Holmes, C., Steart, P., Markham, H., Weller, R.O., Neuropathology of human Alzheimer disease after immunization with amyloidbeta peptide: a case report (2003) Nat Med, 9, pp. 448-452
Noguchi, M., Yoshita, M., Matsumoto, Y., Ono, K., Iwasa, K., Yamada, M., Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration (2005) J Neurol Sci, 237, pp. 61-65
Oddo, S., LaFerla, F.M., The role of nicotinic acetylcholine receptors in Alzheimer's disease (2006) J Physiol Paris, 99, pp. 172-179
Ohno, M., Sametsky, E.A., Younkin, L.H., Oakley, H., Younkin, S.G., Citron, M., Vassar, R., Disterhoft, J.F., BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease (2004) Neuron, 41, pp. 27-33
Otto, M., Esselmann, H., Schulz-Shaeffer, W., Neumann, M., Schroter, A., Ratzka, P., Cepek, L., Wiltfang, J., Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease (2000) Neurology, 54, pp. 1099-1102
Palop, J.J., Mucke, L., Epilepsy and cognitive impairments in Alzheimer disease (2009) Arch Neurol, 66, pp. 435-440
Palop, J.J., Chin, J., Roberson, E.D., Wang, J., Thwin, M.T., Bien-Ly, N., Yoo, J., Mucke, L., Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease (2007) Neuron, 55, pp. 697-711
Panza, F., Solfrizzi, V., Frisardi, V., Capurso, C., D'Introno, A., Colacicco, A.M., Vendemiale, G., Imbimbo, B.P., Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators (2009) Drugs Aging, 26, pp. 537-555
Patton, R.L., Kaiback, W.M., Esh, C.L., Kokjohn, T.A., Van Vickie, G.D., Luehrs, D.C., Kuo, Y.M., Roher, A.E., Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis (2006) Am J Pathol, 169, pp. 1048-1063
Pettit, D.L., Shao, Z., Yakel, J.L., beta-Amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice (2001) J. Neuro. sci., 21, p. RC120
Plant, L.D., Boyle, J.P., Smith, I.F., Peers, C., Pearson, H.A., The production of amyloid beta peptide is a critical requirement for the viability of central neurons (2003) J. Neuro. sci., 23, pp. 5531-5535
Puzzo, D., Privitera, L., Leznik, E., Fa, M., Staniszewski, A., Palmeri, A., Arancio, O., Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus (2008) J. Neuro. sci., 28, pp. 14537-14545
Qiu, W.Q., Folstein, M.F., Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis (2006) Neurobiol Aging, 27, pp. 190-198
Roselli, F., Tirard, M., Lu, J., Hutzler, P., Lamberti, P., Livrea, P., Morabito, M., Almeida, O.F., Soluble betaamyloid 1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses (2005) J. Neuro. sci., 25, pp. 11061-11070
Rowan, M.J., Klyubin, I., Wang, Q., Anwyl, R., Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies (2005) Biochem Soc Trans, 33, pp. 563-567
Sabayan, B., Foroughinia, F., Mowla, A., Borhanihaghighi, A., Role of insulin metabolism disturbances in the development of Alzheimer disease: mini review (2008) Am J Alzheimers Dis Other Deinen, 23, pp. 192-199
Salloway, S., Sperling, R., Oilman, S., Fox, N.C., Blennow, K., Raskind, M., Sabbagh, M., Grundman, M., A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease (2009) Neurology, 73, pp. 2061-2070
Schenk, D., Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse (1999) Nature, 400, pp. 173-177
Senechal, Y., Kelly, P.H., Dev, K.K., Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning (2008) Behav Brain Res, 186, pp. 126-132
Sensi, S.L., Paoletti, P., Bush, A.I., Sekler, I., Zinc in the physiology and pathology of the CNS (2009) Nat Rev Neuro sci, 10, pp. 780-791
Sjogren, M., Davidsson, P., Wallin, A., Granerus, A.K., Grundstrom, E., Askmark, H., Vanmechelen, E., Blennow, K., Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms (2002) Dement Geriatr Cogn Disord, 13, pp. 112-118
Snyder, E.M., Nong, Y., Almeida, C.G., Paul, S., Moran, T., Choi, E.Y., Nairn, A.C., Greengard, P., Regulation of NMDA receptor trafficking by amyloid-beta (2005) Nat Neurosci, 8, pp. 1051-1058
Soto, C., Kindy, M.S., Baumann, M., Frangione, B., Inhibition of Alzheimer's amytoidosis by peptides that prevent beta-sheet conformation (1996) Biochem Biophys Res Commun, 226, pp. 672-680
Soucek, T., Gumming, R., Dargusch, R., Maher, P., Schubert, D., The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide (2003) Neuron, 39, pp. 43-56
Sun, X., Chiu, C.C., Liebson, E., Crivello, N.A., Wang, L., Claunch, J., Folstein, M., Qiu, W.Q., Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele (2009) Alzheimer Dis Assoc Disord, 23, pp. 238-244
Teplow, D.B., Structural and kinetic features of amyloid beta-protein fibrillogenesis (1980) Amyloid, 5, pp. 121-142
Town, T., Alternative Abeta immunotherapy approaches for Alzheimer's disease (2009) CNS Neural Disord Drug Targets, 8, pp. 114-127
Townsend, M., Shankar, G.M., Mehta, T., Walsh, D.M., Selkoe, D.J., Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role fortrimers (2006) J Physiol, 572, pp. 477-492
Vassar, R., Kovacs, D.M., Yan, R., Wong, P.C., The betasecretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential (2009) J. Neuro. sci., 29, pp. 12787-12794
Walsh, D.M., Klyubin, I., Fadeeva, I.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., Selkoe, D.J., Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo (2002) Nature, 416, pp. 535-539
Wang, H., Song, L., Laird, F., Wong, P.C., Lee, H.K., BACE1 knock-outs display deficits in activitydependent potentiation of synaptic transmission at mossy fiber to CA3 synapses in the hippocampus (2008) J. Neuro. sci., 28, pp. 8677-8681
Wang, H.W., Pasternak, J.F., Kuo, H., Ristic, H., Lambert, M.P., Chromy, B., Viola, K.L., Trommer, B.L., Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyms (2002) Brain Res, 924, pp. 133-140
West, A.E., Griffith, E.C., Greenberg, M.E., Regulation of transcription factors by neuronal activity (2002) Nat Rev Neurosci, 3, pp. 921-931
Whitson, J.S., Selkoe, D.J., Cotman, C.W., Amyloid beta protein enhances the survival of hippocampal neurons in vitro (1989) Science, 243, pp. 1488-1490
Wilcock, G.K., Black, S.E., Hendrix, S.B., Zavitz, K.H., Swabb, E.A., Laughlin, M.A., Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial (2008) Lancet Neurol, 7, pp. 483-493
Wisniewski, T., Konietzko, U., Amyloid-beta immunisation for Alzheimer's disease (2008) Lancet Neurol, 7, pp. 805-811
Xia, W., Yang, T., Shankar, G., Smith, I.M., Shen, Y., Walsh, D.M., Selkoe, D.J., A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease (2009) Arch Neurol, 66, pp. 190-199
Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M.B., Teplow, D.B., Haass, C., Selkoe, D.J., Enhanced production and oligomerization of the 42-residue amyloid betaprotein by Chinese hamster ovary cells stably expressing mutant presenilins (1997) J Biol Chem, 272, pp. 7977-7982
Kállay C, Dávid A, Timári S, Nagy EM, Sanna D, Garribba E, Micera G, De Bona P, Pappalardo G, Rizzarelli E, Sóvágó I * Copper(II) complexes of rat amylin fragments(357 views) Dalton T (ISSN: 1477-9234, 1477-9226, 1477-9234electronic), 2011 Oct 14; 40(38): 9711-9721. Impact Factor:3.838 ViewExport to BibTeXExport to EndNote
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(761 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote